期刊文献+

痛风舒缓胶囊急性毒性实验研究 被引量:2

The acute toxic study of Tongfengshuhuan Capsule
下载PDF
导出
摘要 目的观察痛风舒缓胶囊(TFSHC)对小鼠有无急性毒性反应,确定TFSHC的安全范围,为指导其临床安全用药提供一定的实验依据。方法将SPF级昆明小鼠40只(雌雄各半)随机分为TFSHC处理组和生理盐水对照组,TFSHC组以54g/kg灌胃,动态观察小鼠体重和摄食量等,14d后处死尸检,观察其心、肝、脾、肺、肾、肾上腺、胸腺、胃、肠、睾丸等脏器是否异常。结果 TFSHC组无1例小鼠死亡,与生理盐水对照组比较,TFSHC组的体重变化和进食量无显著差异,行为活动等无异常,尸解后未见TFSHC组动物的脏器异常。结论给予小鼠TFSHC最大剂量54g/kg并未见急性毒性反应,其耐受人用量口服的750倍,较为安全,TFSHC值得进一步研究开发。 Objective To observe the acute toxicity of TongFengShuHuan Capsule(TFSHC) in mice and to provide the experimental data for clinical drug safety.Methods The SPF level mice were randomly divided into the treatment group of TFSHC and the normal sodium control group.The number of female and male mice for each group was ten respectively.TFSHC-treatment group was administered intragastrically 54g/kg.The changes of the body weigh and feed intake of animals were measured dynamically.After 14 days,all animals were killed and autopsied.Then the internal organs were observed,which included heart,liver,spleen,lung,kidney,adrenal gland,thymus,stomach,intestine,testis,and so on.Results The mortality was 0 in two treatment groups.Compared with the saline control group,the change of the food intake and the body weight were not significantly different in TFSHC-treatment group.The general conditions of animals were not abnormal in TFSHC-treatment group.After the gross anatomy,the appearance of organ were not abnormal.Conclusions There is not existed for the acute toxicity in TFSHC-treatment mice with the maximum dose of 54g/kg.The Tolerant multiple is 750 times for the clinical use of the drugs.It is worth to do further study for TFSHC Capsule.
出处 《遵义医学院学报》 2011年第4期327-329,共3页 Journal of Zunyi Medical University
关键词 痛风 痛风舒缓胶囊 最大给药剂量 急性毒性 小鼠 gout Tongfengshuhuan Capsule maximum tolerated dose acute toxicity mice
  • 相关文献

参考文献6

二级参考文献24

  • 1梁德荣,徐楠,张辉明,蔡永宁,张慧琳.苯溴马龙与磺丙舒治疗痛风的随机对照研究[J].华西医学,1994,9(4):405-408. 被引量:10
  • 2Jinnah HA, De-Gregorio L, Harris JC et al. The spectrum of inherited mutations causing HPRT deficiency- 75 new cases and a review of 196 previously reported cases. MutatRes, 2000;463(3):309-26. 被引量:1
  • 3Chang SJ, Chang JG, Chen CJ et al. Identification of a new single nucleotide substitution on the hypoxanthine-guanine phosphoribosyltransferase gene (HPRT(Tsou)) from a Taiwan Residents aboriginal family with severe gout. J Rheumatol, 1999;26(8) :1802-7. 被引量:1
  • 4Nyhan WL. Dopamine function in Lesch-Nyhan disease. Environ Health Perspect ,2000;108(Suppl 3):409-11. 被引量:1
  • 5Chou JY, Matern D, Mansfield BC, Chen YT. Type I glycogen storage diseases: Disorders of the glucose-6-phosphatase complex. Curr Mol Med, 2002;2(2) :121-43. 被引量:1
  • 6Matern D, Seydewitz HH, Bali D et al. Glycogen storage disease type I:Diagnosis and phenotype/genotype correlation. Eur J Pediatr ,2002 ; 161(Suppl 1) : 10-9. 被引量:1
  • 7Arromdee E, Michet CJ, Crowson CS et al. Epidemiology of gout is the incidence rising? J Rheumato1,2002 ;29(11):2403-6. 被引量:1
  • 8Yu KH, Luo SF. Younger age of onset of gout in Taiwan.Rheumatology (Oxford) ,2003 ;42(1): 166-70. 被引量:1
  • 9Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan:Results from the nutritional and health surveyin Taiwan (1993-96). J Rheumatol, 2001 ;28(7) :1640-6. 被引量:1
  • 10Tomita M, Mizuno S, Yamanaka H, Hosoda Y. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol, 2000;10 (6) : 403 - 9. 被引量:1

共引文献121

同被引文献6

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部